Welcome to our dedicated page for Telix Pharmaceuticals SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telix Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telix Pharmaceuticals's regulatory disclosures and financial reporting.
Telix Pharmaceuticals Limited has priced and upsized a US$600 million Offering of 1.50% convertible bonds due on or about 22 April 2031, issued by its U.S. subsidiary and guaranteed by Telix and a U.S. affiliate. The Convertible Bonds are convertible into Telix ordinary shares at an initial conversion price of US$13.85 (~A$19.55) per share, a 37.5% premium to a A$14.22 reference share price. Telix will concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029, with the balance intended to be redeemed, materially extending its debt maturity profile. Settlement of the new Offering and the Concurrent Repurchase is expected on 22 April 2026, subject to customary conditions, and is supported by a stock borrow facility over 15 million shares for 11 months.
Telix Pharmaceuticals is launching an offering of US$550 million convertible notes due 2031 through a wholly owned subsidiary, guaranteed by Telix entities, to refinance its existing 2029 convertible bonds and fund general corporate purposes. The notes carry an expected coupon of 1.50–1.75% and a 35–37.5% conversion premium, with a 5‑year maturity and an investor put after year three.
The company also highlights strong recent performance, with 2025 group revenue of US$804 million, up 56% year over year, including US$622 million from Precision Medicine and US$40 million EBITDA. Q1 2026 revenue reached US$230 million, up 11% sequentially, and 2026 revenue guidance is US$950–970 million. Telix outlines a late‑stage radiopharma pipeline, near‑term regulatory milestones and a new collaboration with Regeneron that includes US$40 million upfront and up to US$2.1 billion in potential milestones.
Telix Pharmaceuticals reports that the U.S. FDA has accepted its resubmitted New Drug Application for TLX101-Px (Pixclara), a PET imaging agent for glioma, and has assigned a PDUFA goal date of September 11, 2026.
TLX101-Px has Orphan Drug and Fast Track designations and is intended to help distinguish recurrent or progressive glioma from treatment-related changes in adults and children. Telix notes that its FY 2026 financial guidance does not include any revenue from TLX101-Px.
Telix Pharmaceuticals Limited has expanded its Board by appointing two additional Non-Executive Directors, effective May 11, 2026, as part of broader succession planning. Maria Rivas, MD brings more than 25 years of experience in late-stage clinical development and commercialization, including service as Chief Medical Officer at Pfizer.
William (Bill) Jellison adds over 30 years of corporate finance and audit committee leadership, having served as Vice President and CFO of Stryker and as a director for multiple U.S. public companies. Telix’s Interim Chair said these appointments support the company’s evolution as a dual-listed, global, commercial-stage biopharmaceutical business focused on radiopharmaceuticals for oncology and rare diseases.
Telix Pharmaceuticals reports strong first-quarter momentum, with unaudited Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% from Q4 2025. Precision Medicine revenue reached US$186 million, rising 23% year-over-year as Illuccix and Gozellix dose volumes and market share increased.
The company reaffirmed its FY 2026 revenue guidance of US$950–970 million and R&D expenditure guidance of US$200–240 million, indicating continued heavy investment in its pipeline. TMS third-party revenue was US$44 million, up 29% year-over-year.
Telix highlighted multiple late-stage pipeline advances, including Part 1 of the global Phase 3 ProstACT trial for TLX591-Tx meeting safety and dosimetry objectives with no new safety signals, first-patient-in for pivotal trials in brain cancer and glioblastoma, and regulatory progress for imaging agents TLX101-Px (NDA resubmission in the U.S. and MAA filing in Europe) and TLX250-Px (preparing a BLA resubmission after successful FDA Type A meetings). Corporate updates include appointing David Gill as a new Non-Executive Director, with an expectation he will become Chair.
Telix Pharmaceuticals Limited has appointed experienced life sciences executive David Gill as a Non-Executive Director as part of its board expansion and succession planning. His appointment is effective May 11, 2026, subject to grant of an Australian Director Identification number.
Gill is expected to become Chair in due course, succeeding Interim Chair Dr. Mark Nelson, who will remain on the board as a Non-Executive Director. Telix also announced that Genevieve Ryan resigned as Company Secretary effective April 2, 2026, with Shomalin Naidoo appointed interim Company Secretary and primary ASX Listing Rule contact from the same date.
Telix Pharmaceuticals Group Chief Financial Officer Darren Charlton Smith exercised previously granted share rights into ordinary shares. On March 29, 2026, he converted 1,111 share rights into 1,111 ordinary shares at an exercise price of $0.00 per share. These share rights were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. Following the transaction, he directly holds 11,921 ordinary shares of Telix Pharmaceuticals Ltd, and the exercised share rights position has been fully used with no remaining derivative balance reported. No open-market sale occurred in this filing; it reflects a routine compensation-related option exercise that increases his direct share ownership.
Telix Pharmaceuticals’ Group Chief Medical Officer, Cade David Norman, has reported his existing equity interests in the company. He holds 373,133 Ordinary Shares directly, along with several derivative awards tied to Telix ordinary shares.
These include Performance Share Appreciation Rights over 78,189 underlying Ordinary Shares at A$4.9500 per share expiring on April 4, 2027, and 84,293 underlying Ordinary Shares at A$6.9000 per share expiring on December 21, 2027. He also holds Share Rights over 1,080 underlying Ordinary Shares expiring on March 31, 2028 and 11,486 underlying Ordinary Shares expiring on March 31, 2029. Footnotes state these awards were granted between April 2022 and March 2026, with vesting dates in 2025–2027 and that each Share Right represents the contingent right to receive one ordinary share, subject to continued employment and forfeiture if employment is terminated for cause.
Telix Pharmaceuticals Ltd director Nelson Mark Alexander has filed an initial Form 3 reporting his existing shareholdings. The filing shows indirect beneficial ownership of 3,628,750 Ordinary Shares held through MAN Holdings Pty Ltd, acting as trustee for the Nelson Hybrid Trust, of which he is a director and shareholder. This filing records his current position rather than any new share purchase or sale.